Anbio Biotechnology (NNNN) Receivables (2023 - 2025)

Anbio Biotechnology has reported Receivables for 3 years, with the latest figure at $3.7 million in Q4 2025.

• For the quarter ending Q4 2025, Receivables rose 243.44% year-over-year to $3.7 million; the trailing twelve-month figure through Dec 2025 stood at $3.7 million (up 243.44% YoY), and the FY2025 full-year result was $3.7 million, up 243.44% from the prior year.
• Receivables for Q4 2025 stood at $3.7 million, up from $1.1 million in the prior quarter.
• The five-year high for Receivables was $3.7 million in Q4 2025, with the low at $1.1 million in Q4 2024.
• Average Receivables over 3 years is $2.2 million, with a median of $1.9 million recorded in 2023.
• Year-over-year, Receivables plunged 43.51% in 2024 and surged 243.44% in 2025.
• Tracing NNNN's Receivables over 3 years: stood at $1.9 million in 2023, then plunged by 43.51% to $1.1 million in 2024, then surged by 243.44% to $3.7 million in 2025.
• The last three Receivables figures came in at $3.7 million (Q4 2025), $1.1 million (Q4 2024), and $1.9 million (Q4 2023), per Business Quant data.

Peer Comparison